The latest biotech news

CSL pays 275m to acquire Novartis flu vaccines manufacturing sites strict xxl

News and Trends 31 Oct 2014

Novartis steps down completely from Vaccines’ Business

Novartis divests its influenza vaccines business to CSL Limited, an Australian company, for an agreed price of 219 million euros, completing the last deal with GSK a few months ago. This is a strategic move of Novartis; they plan to focus on the pharmaceutical business, ophthalmology (Alcon) and generics (Sandoz). Last year, influenza vaccine business reached a turnover of 1 […]

October 31, 2014 - 2 minutesmins - By Julie Lellouche

News and Trends 30 Oct 2014

Review : Ebola, The True Story

The first outbreaks of Ebola (also known as Ebola haemorrhagic fever) have occurred in isolated villages in central Africa, near tropical forests, but the recent outbreak in West Africa has affected major urban centers as well as rural areas. The Ebola virus disease shows an average fatality rate about 50%. In previous outbreaks, the rate […]

October 30, 2014 - 26 minutesmins - By Cédric Brock

News and Trends 29 Oct 2014

Sanofi Fires its CEO Chris Viehbacher

Breaking news for French Pharma company Sanofi. The Board decided to fire Christopher Viehbacher, who was leading the company since December 2008. Chris Viehbacher, German-Canadian, was the first non-French CEO of Sanofi, second largest French company. He had a tough management and tried to transform Sanofi (maybe too much). He managed Sanofi’s transition to Biotech/Biologicals with […]

October 29, 2014 - 2 minutesmins - By Philip Hemme

News and Trends 28 Oct 2014

Stem Cell Therapy for Degenerative Muscle Disease thanks to ENDOSTEM Project

ENDOSTEM project aims to identify an agent capable of ‘boosting’ stem cells already present in muscle tissue for a more efficient tissue repair to tackle degenerative muscle disease. Muscular dystrophy is a type of degenerative muscle disease. One of its most known forms, Duchenne muscular dystrophy, affects 1 over 3 500 boys worldwide. It affects patients progressively, they […]

October 28, 2014 - 3 minutesmins - By Julie Lellouche

News and Trends 27 Oct 2014

Forendo Pharma Closes 12 Million Euros to Develop Novel Targeted Therapy

Forendo Pharma successfully closed €12M for further development of treatment against endometriosis. Novartis Venture Fund and MS Ventures will participate in the financing round, alongside the current major shareholders Karolinska Development, Novo A/S and Finnvera. Endometriosis is a chronic disease affecting up to 10% of the women between adolescence and menopause. There is a large unmet medical […]

October 27, 2014 - 2 minutesmins - By Julie Lellouche

News and Trends 25 Oct 2014

Belgian Promethera received approval to start World first Phase IIb/III stem-cell based urea cycle disorders treatment

Promethera is a promising Belgian Biotechnology company developing stem-cell based treatment against liver diseases. It was created in 2009, counts 44 employees and has raised €39M. The company now moves to another level by starting its own Phase IIb/III to treat paediatric patients with urea cycle disorders. It is the first company in the World […]

October 25, 2014 - 1 minutemin - By Philip Hemme

News and Trends 24 Oct 2014

Only One Woman for Ten Men in 2014 Biotech Boards

The average board of directors in the biotech world is roughly 90% male, and more than half of all industry boardrooms host no women. Recent report from Lifestream release these striking numbers that illustrate a sector that struggles with diversity. Nearly 1,150 life sciences companies in the U.S. and EU, finding that biotech’s boardrooms tend […]

October 24, 2014 - 1 minutemin - By Julie Lellouche

News and Trends 23 Oct 2014

The First French Biotech entered successfully on the NASDAQ

DBV Technologies entered on the NASDAQ last Wednesday raising up to 90 million euros. It bets on treating peanut allergy, which is a major health issue in the United States, and targets up to one billion dollars revenues. The small French biotechnology company which has developed a new system of allergy desensitization based on skin patches launched […]

October 23, 2014 - 2 minutesmins - By Julie Lellouche

News and Trends 22 Oct 2014

New Treatment against critic Leukemia Approved In Europe

Janssen’s Imbruvica (ibrutinib), the once-daily oral Bruton’s tyrosine kinase (BTK) inhibitor, has been approved in Europe as a treatment for two blood cancers. The drug has been ratified by the European Commission for the treatment of adult patients with relapsed or refractory mantle cell lymphoma, or chronic lymphocytic leukemia. The therapy functions block BTK, a protein […]

October 22, 2014 - 2 minutesmins - By Julie Lellouche

News and Trends 20 Oct 2014

European’s First Personalized Vaccines to Treat Brain Cancer

A novel concept of fully personalized therapeutic cancer vaccines, called Glioma Actively Personalized VAccine Consortium (GAPVAC), has been moved into the clinic. It is the first european approval for such a technology. The project is lead by two german Biotech companies Immatics biotechnologies and BioNTech, and received a €6 million grant from European Union. The German National Authorities has approved the […]

October 20, 2014 - 3 minutesmins - By Julie Lellouche

10486567 10152342154846513 5707030158597204448 o

News and Trends 18 Oct 2014

One Week European Biotech Industry Celebration

The European Biotech Week was celebrated for the second time at the beggining of October. It was an important event to discuss and develop biotechnology in Europe. The European Biotech Week was organized by EuropaBio, european organization for Biotech companies. It was also an opportunity to bring together biotech associations because they are key in helping to […]

October 18, 2014 - 1 minutemin - By Julie Lellouche

News and Trends 17 Oct 2014

Should European Biotech CEOs wear more sneakers?

Today is Friday or Casual Day. Did you leave the suit and the tie at home to wear jeans and sneakers? Should you have done so? More and more people do so on Friday but also the rest of the week. The American Tech industry and the Silicone Valley started the movement. Steve Jobs is probably the most […]

October 17, 2014 - 3 minutesmins - By Philip Hemme

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

News and Trends

Novartis steps down completely from Vaccines’ Business

Review : Ebola, The True Story

Sanofi Fires its CEO Chris Viehbacher

Stem Cell Therapy for Degenerative Muscle Disease thanks to ENDOSTEM Project

Forendo Pharma Closes 12 Million Euros to Develop Novel Targeted Therapy

Belgian Promethera received approval to start World first Phase IIb/III stem-cell based urea cycle disorders treatment

Only One Woman for Ten Men in 2014 Biotech Boards

The First French Biotech entered successfully on the NASDAQ

New Treatment against critic Leukemia Approved In Europe

European’s First Personalized Vaccines to Treat Brain Cancer

One Week European Biotech Industry Celebration

Should European Biotech CEOs wear more sneakers?

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!